Skip to Main Content
Contribute Try STAT+ Today

Nearly two months ago, a U.S. bankruptcy court judge approved a controversial Purdue Pharma plan that would funnel billions of dollars to pay for the harm caused by the OxyContin opioid painkiller.

At the core, the deal calls for some members of the Sackler family — which controlled Purdue — to contribute more than $4.3 billion over nearly a decade to compensate individuals, state and local governments, and tribal communities for the cost of the opioid crisis. The deal was in response to some 3,000 lawsuits that prompted the company to seek bankruptcy in 2019. But even though the plan was approved, the money hasn’t started flowing and it remains unclear when that will happen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment